1. Home
  2. DWSN vs CRDF Comparison

DWSN vs CRDF Comparison

Compare DWSN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DWSN

Dawson Geophysical Company

HOLD

Current Price

$4.26

Market Cap

124.5M

Sector

Energy

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.52

Market Cap

114.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DWSN
CRDF
Founded
1952
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
114.2M
IPO Year
1995
2012

Fundamental Metrics

Financial Performance
Metric
DWSN
CRDF
Price
$4.26
$1.52
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
107.3K
1.6M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
53.85
27.37
EPS
0.25
N/A
Revenue
$145,773,000.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.72
N/A
Revenue Growth
N/A
49.61
52 Week Low
$1.27
$1.35
52 Week High
$5.54
$4.56

Technical Indicators

Market Signals
Indicator
DWSN
CRDF
Relative Strength Index (RSI) 58.94 43.70
Support Level $1.63 N/A
Resistance Level $4.93 $1.76
Average True Range (ATR) 0.35 0.16
MACD -0.01 -0.03
Stochastic Oscillator 75.97 26.15

Price Performance

Historical Comparison
DWSN
CRDF

About DWSN Dawson Geophysical Company

Dawson Geophysical Co provides seismic data acquisition services mainly to providers of multi-client data libraries and directly to onshore oil and natural gas exploration and development companies in the continental U.S. and Canada. The demand for seismic services is largely influenced by drilling and completion activity, exploration budgets, and prevailing and anticipated crude oil and natural gas prices. Its data acquisition crews serve companies engaged in the exploration and development of oil and gas on land and in land-to-water transition areas. The business operates through two reportable segments, with U.S. operations generating the majority of revenue and Canada operations contributing additionally.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: